- Home
- PCSA vs ATNF Comparison
PCSA vs ATNF Comparison
Compare PCSA & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- ATNF
- Stock Information
- Founded
- PCSA 2011
- ATNF 2016
- Country
- PCSA United States
- ATNF United States
- Employees
- PCSA 13
- ATNF N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- PCSA Health Care
- ATNF Health Care
- Exchange
- PCSA Nasdaq
- ATNF Nasdaq
- Market Cap
- PCSA 3.3M
- ATNF 3.8M
- IPO Year
- PCSA N/A
- ATNF N/A
- Fundamental
- Price
- PCSA $0.22
- ATNF $0.83
- Analyst Decision
- PCSA Strong Buy
- ATNF
- Analyst Count
- PCSA 1
- ATNF 0
- Target Price
- PCSA $6.00
- ATNF N/A
- AVG Volume (30 Days)
- PCSA 46.5M
- ATNF 35.4K
- Earning Date
- PCSA 08-12-2025
- ATNF 08-11-2025
- Dividend Yield
- PCSA N/A
- ATNF N/A
- EPS Growth
- PCSA N/A
- ATNF N/A
- EPS
- PCSA N/A
- ATNF N/A
- Revenue
- PCSA N/A
- ATNF N/A
- Revenue This Year
- PCSA N/A
- ATNF N/A
- Revenue Next Year
- PCSA N/A
- ATNF N/A
- P/E Ratio
- PCSA N/A
- ATNF N/A
- Revenue Growth
- PCSA N/A
- ATNF N/A
- 52 Week Low
- PCSA $0.15
- ATNF $0.66
- 52 Week High
- PCSA $3.10
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- PCSA 44.28
- ATNF 35.60
- Support Level
- PCSA $0.20
- ATNF $0.95
- Resistance Level
- PCSA $0.33
- ATNF $1.04
- Average True Range (ATR)
- PCSA 0.09
- ATNF 0.08
- MACD
- PCSA -0.01
- ATNF -0.01
- Stochastic Oscillator
- PCSA 6.53
- ATNF 17.41
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.